Novartis Q2 2025 Earnings: Strong Growth, Innovation Pipeline Driving Future

On July 17, Novartis released its Q2 2025 earnings flash report. The highlights are summarized below:

I. Core Financial Performance: A Comprehensive Win with Double-Digit Growth

• Revenue: Q2 net sales reached $14.05 billion (up 12% year-over-year, +11% at constant currency), totaling $27.29 billion in h2 (+13% cc). Growth was primarily driven by key products, with sales of Kisqali (breast cancer drug) soaring 64%, Entresto (heart failure treatment) rising 22%, and Pluvicto (prostate cancer therapy) growing 30%.
• Profit Margin Expansion: Core operating margin hit 42.2%, a 340-basis-point increase year-over-year, reflecting product mix optimization and improved operational efficiency.
• Cash Flow: Q2 free cash flow reached $6.3 billion (+37%), providing ample resources for strategic initiatives.

CEO Vas Narasimhan emphasized: "Our ability to translate the pipeline continues to deliver. The commercial success of Pluvicto, Kisqali, and others demonstrates the replacement power of our innovative portfolio."

II. Star Product Matrix: Strong Results Across Multiple Fields

Novartis' "Four-Core Therapeutic Areas" strategy (Cardio-Metabolic, Immunology, Neuroscience, Oncology) has proven effective:

Oncology

• Kisqali: Early breast cancer indication drove over 100% growth in the U.S. market.
• Pluvicto: Phase III study (PSMAddition) in prostate cancer met its primary endpoint and will be submitted for regulatory approval.
• Scemblix (leukemia drug): Sales surged 79% year-over-year.

Cardio-Metabolic

• Entresto: Global demand remained strong, with 22% growth.
• Leqvio (cholesterol-lowering drug): Patient adoption drove 61% growth.

Emerging Technology Platforms

• Gene Therapy: OAV101 filing completed in the U.S. and Europe.
• Radioligand Therapy: Pluvicto's Phase III data was promising, validating Novartis' positioning in advanced areas like xRNA and radiopharmaceuticals.

III. R&D Milestones: Accelerating Future Growth Engines

• Key Approvals: Vanrafia (IgA nephropathy) received FDA accelerated approval; Coartem Baby (malaria drug) approved in Switzerland.
• Clinical Breakthroughs: Votoplam for Huntington’s disease met primary endpoints in Phase II; positive Phase II results for food allergy treatment remibrutinib.
• Strategic Acquisition: Completed acquisition of Regulus Therapeutics (microRNA therapy), enhancing kidney disease pipeline.

IV. Capital Operations and 2025 Outlook

• Share Buyback: Launched a $10 billion share repurchase program (to be completed by end-2027).
• Dividend Policy: $7.8 billion in dividends paid in h2.
• Upgraded Guidance: Raised 2025 core operating profit growth forecast from “low double digits” to “low teens.”

Risk Alert: Entresto may face generic competition in the U.S. mid-year, but management remains confident in long-term growth.

V. Strategic Focus: Advancing Toward a Pure-Play Innovative Pharma Company

Novartis’ three strategic pillars are clearly defined:

• Accelerated Growth: Focus on high-value new molecular entities (NMEs), with 80% of the pipeline having potential blockbuster status.
• Platform Expansion: Prioritizing gene therapy, radioligands, and xRNA technologies.
• Geographic Expansion: U.S., China, Germany, and Japan together contribute over 60% of revenue.

Novartis’ Q2 results underscore its successful transformation into a “pure-play innovative pharma” company. With strong product momentum, efficient pipeline execution, and disciplined capital allocation, the company is not only achieving its short-term financial goals but also laying a solid foundation for sustained long-term growth. As new-generation therapies like Pluvicto gain traction and cutting-edge technologies such as gene editing continue to advance, Novartis is well positioned to maintain industry leadership over the next five years.